Pacira | PCRX - Gross Profit On Sales

Stock Price
26.23
Daily Change
-0.23 -0.85%
Monthly
4.11%
Yearly
98.22%
Q3 Forecast
26.23

Pacira reported $125.91M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.54B
Cash and Equivalent USD 300.48M
Cost of Sales USD 55.19M
Current Assets USD 745.61M
Current Liabilities USD 313.16M
Debt USD 580.49M
EBIT USD 10.23M
EBITDA USD 54.32M
Employees USD 790
EPS Earnings Per Share USD 0.74
Equity Capital and Reserves USD 757.77M
Gross Profit on Sales USD 125.91M
Interest Expense on Debt USD 3.82M
Interest Income USD 5.01M
Loan Capital USD 378.1M
Market Capitalization USD 1.22B
Net Income USD -4.85M
Operating Expenses USD 170.87M
Operating Profit USD 10.23M
Ordinary Share Capital USD 44.9M
PE Price to Earnings USD 23.09
Pre-Tax Profit USD -1.93M
Sales Revenues USD 181.1M
Selling and Administration Expenses USD 77.2M
Stock USD 148.16M
Trade Creditors USD 30.12M
Trade Debtors USD 114.37M

Gross Profit On Sales Change Date
Astellas Pharma JPY 410.96B 28.53B Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Ironwood Pharmaceuticals USD 3.65M 60.36M Sep/2024
J&J USD 14.6B 816M Mar/2025
Ligand Pharmaceuticals USD 72.86M 32.38M Jun/2025
Novo Nordisk 64.01B 1.19B Jun/2025
Pacira USD 125.91M 8.71M Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Supernus Pharmaceuticals USD 127.81M 6.25M Jun/2025
Teva Pharmaceutical Industries USD 2.1B 188M Jun/2025
Xeris Pharmaceuticals USD 59.64M 9.02M Jun/2025
Zoetis USD 1.78B 180M Jun/2025